Simons L A
University of New South Wales, Australia.
Aust Fam Physician. 1996 Jul;25(7):1053-9.
Abnormalities in serum lipids are important predictors of coronary artery disease. Lipid therapy safely reduces the future risk of coronary disease and simultaneously improves life expectancy. These benefits have been demonstrated in patients with and without-prior heart disease. Lipid therapy needs to be prioritized for those at highest absolute risk of coronary disease, that is, in those with established coronary disease or in those with other major risk factors such as diabetes, a positive family history of coronary disease, low high density lipoprotein (HDL) cholesterol level, hypertension or cigarette smoking. Drug selection is discussed, as is the place of lipid therapy in the elderly. Many patients fail to continue their lipid therapy beyond a few weeks and this problem needs to be considered by the general practitioner.
血清脂质异常是冠状动脉疾病的重要预测指标。脂质治疗可安全降低未来患冠心病的风险，同时提高预期寿命。这些益处已在有或无心脏病史的患者中得到证实。脂质治疗需要优先用于冠心病绝对风险最高的人群，即已确诊冠心病的患者或有其他主要危险因素的人群，如糖尿病、冠心病家族史阳性、高密度脂蛋白（HDL）胆固醇水平低、高血压或吸烟。文中讨论了药物选择以及脂质治疗在老年人中的地位。许多患者在几周后就不再继续进行脂质治疗，全科医生需要考虑这个问题。
